Skip to main content
SpringerLink
Log in

Aktueller Stand der spezifischen Immuntherapie mit Tierepithelien

Allergen-specific immunotherapy in pet allergy – an update

  • Leitthema
  • Published:
Der Hautarzt Aims and scope Submit manuscript

Zusammenfassung

Tierepithelien sind ein häufiger Auslöser für die allergische Rhinitis und das allergische Asthma bronchiale. Beim Menschen stellen Katzen und Hunde die Hauptursachen für eine Allergie gegenüber Tierepithelien dar. Eine wichtige Säule der Therapie bei entsprechender klinisch manifester Allergie ist die Eliminierung des Haustieres aus dem häuslichen Umfeld als sog. Karenzmaßnahme (sekundäre Prävention). Das Meiden der Exposition oder des indirekten Kontaktes gegenüber Katzen ist oftmals schwierig, da insbesondere bei dem Katzenallergen gute Schwebeeigenschaften eine nahezu ubiquitäre Verschleppung der Allergene ermöglichen. Die konventionelle pharmakologische Therapie ist nicht immer suffizient in der Behandlung von Patienten. Als Therapiemöglichkeit besteht die Behandlung mittels der kausalen allergenspezifischen Immuntherapie (SIT), über deren aktuellen Stand und zukünftige Entwicklungen bei der Katzenallergie im vorliegenden Beitrag eine Übersicht gegeben wird.

Abstract

Animal dander is a common cause of allergic rhinitis and allergic asthma in patients. In this regard, cats and dogs represent major causes of allergy to animal dander. In first line, the therapeutic options include the elimination of the pet from the patient’s home as a (secondary) preventive step. However, avoidance of temporary contacts or indirect exposure to cat dander is often difficult, since cat-allergens are widely distributed even in non-catkeeping households. In general, conventional pharmacologic therapy does not thoroughly prevent allergic symptoms. Therefore, allergen-specific immunotherapy (SIT) represents an important therapeutic option. This article highlights the current standards and further developments of SIT for cat-allergic patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Heutelbeck ARR (2005) Präventaion allergischer Atemwegserkrankungen durch Katzenallergene. Allergo J 14:190–197

    Google Scholar 

  2. Schafer T, Wolke G, Ring J et al (2007) Allergic sensitization to cat in childhood as major predictor of incident respiratory allergy in young adults. Allergy 62(11):1282–1287

    Article  PubMed  CAS  Google Scholar 

  3. Maniu CM, Hunezlmann N, Schuster JC (2008) Katzenallergie: aktualisierte Datenlage zu Epidemiologie und Therapie und Neues aus der Molekularbiologie von Fel d 1. Allergo J 10(31):410–421

    Google Scholar 

  4. Enberg RN, Shamie SM, McCullough J, Ownby DR (1993) Ubiquitous presence of cat allergen in cat-free buildings: probable dispersal from human clothing. Ann Allergy 70(6):471–474

    PubMed  CAS  Google Scholar 

  5. Wentz PE, Swanson MC, Reed CE (1990) Variability of cat-allergen shedding. J Allergy Clin Immunol 85(1 Pt 1):94–98

    Article  PubMed  CAS  Google Scholar 

  6. Charpin C, Zielonka TM, Charpin D et al (1994) Effects of castration and testosterone on Fel dI production by sebaceous glands of male cats: II – Morphometric assessment. Clin Exp Allergy 24(12):1174–1178

    Article  PubMed  CAS  Google Scholar 

  7. Wallace DV (2009) Pet dander and perennial allergic rhinitis: therapeutic options. Allergy Asthma Proc 30(6):573–583

    Article  PubMed  Google Scholar 

  8. Avner DB, Perzanowski MS, Platts-Mills TA, Woodfolk JA (1997) Evaluation of different techniques for washing cats: quantitation of allergen removed from the cat and the effect on airborne Fel d 1. J Allergy Clin Immunol 100(3):307–312

    Article  PubMed  CAS  Google Scholar 

  9. Fahlbusch B, Gehring U, Richter K et al (2002) Predictors of cat allergen (Fel d 1) in house dust of German homes with/without cats. J Investig Allergol Clin Immunol 12(1):12–20

    PubMed  CAS  Google Scholar 

  10. Pfaar O, Klimek L (2008) Specific immunotherapy for allergic rhinitis. Current methods and innovative developments. HNO 56(8):764–775

    Article  PubMed  CAS  Google Scholar 

  11. Varney VA, Edwards J, Tabbah K et al (1997) Clinical efficacy of specific immunotherapy to cat dander: a double-blind placebo-controlled trial. Clin Exp Allergy 27(8):860–867

    Article  PubMed  CAS  Google Scholar 

  12. Ohman JL Jr, Findlay SR, Leitermann KM (1984) Immunotherapy in cat-induced asthma. Double-blind trial with evaluation of in vivo and in vitro responses. J Allergy Clin Immunol 74(3 Pt 1):230–239

    Article  PubMed  Google Scholar 

  13. Taylor WW, Ohman JL Jr, Lowell FC (1978) Immunotherapy in cat-induced asthma. Double-blind trial with evaluation of bronchial responses to cat allergen and histamine. J Allergy Clin Immunol 61(5):283–287

    Article  PubMed  CAS  Google Scholar 

  14. Van MT Jr, Marsh DG, Adkinson NF Jr et al (1988) Immunotherapy for cat asthma. J Allergy Clin Immunol 82(6):1055–1068

    Article  Google Scholar 

  15. Hedlin G, Graff-Lonnevig V, Heilborn H et al (1991) Immunotherapy with cat- and dog-dander extracts. V. Effects of 3 years of treatment. J Allergy Clin Immunol 87(5):955–964

    Article  PubMed  CAS  Google Scholar 

  16. Ewbank PA, Murray J, Sanders K et al (2003) A double-blind, placebo-controlled immunotherapy dose-response study with standardized cat extract. J Allergy Clin Immunol 111(1):155–161

    Article  PubMed  CAS  Google Scholar 

  17. Nanda A, O’connor M, Anand M et al (2004) Dose dependence and time course of the immunologic response to administration of standardized cat allergen extract. J Allergy Clin Immunol 114(6):1339–1344

    Article  PubMed  CAS  Google Scholar 

  18. Lilja G, Sundin B, Graff-Lonnevig V et al (1989) Immunotherapy with cat- and dog-dander extracts. IV. Effects of 2 years of treatment. J Allergy Clin Immunol 83(1):37–44

    Article  PubMed  CAS  Google Scholar 

  19. Sundin B, Lilja G, Graff-Lonnevig V et al (1986) Immunotherapy with partially purified and standardized animal dander extracts. I. Clinical results from a double-blind study on patients with animal dander asthma. J Allergy Clin Immunol 77(3):478–487

    Article  PubMed  CAS  Google Scholar 

  20. Esch RE, Bush RK, Peden D, Lockey RF (2008) Sublingual-oral administration of standardized allergenic extracts: phase 1 safety and dosing results. Ann Allergy Asthma Immunol 100(5):475–481

    Article  PubMed  Google Scholar 

  21. Nelson HS, Oppenheimer J, Vatsia GA, Buchmeier A (1993) A double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized cat extract. J Allergy Clin Immunol 92(2):229–236

    Article  PubMed  CAS  Google Scholar 

  22. Oppenheimer J, Areson JG, Nelson HS (1994) Safety and efficacy of oral immunotherapy with standardized cat extract. J Allergy Clin Immunol 93(1 Pt 1):61–67

    Article  PubMed  CAS  Google Scholar 

  23. Sanchez PA, Schamann F, Garcia JA (2001) Sublingual immunotherapy with cat epithelial extract. Personal experience. Allergol Immunopathol (Madr) 29(2):60–65

    Google Scholar 

  24. Alvarez-Cuesta E, Berges-Gimeno P, Gonzalez-Mancebo E et al (2007) Sublingual immunotherapy with a standardized cat dander extract: evaluation of efficacy in a double blind placebo controlled study. Allergy 62(7):810–817

    Article  PubMed  CAS  Google Scholar 

  25. Norman PS, Ohman JL Jr, Long AA et al (1996) Treatment of cat allergy with T-cell reactive peptides. Am J Respir Crit Care Med 154(6 Pt 1):1623–1628

    PubMed  CAS  Google Scholar 

  26. Maguire P, Nicodemus C, Robinson D et al (1999) The safety and efficacy of ALLERVAX CAT in cat allergic patients. Clin Immunol 93(3):222–231

    Article  PubMed  CAS  Google Scholar 

  27. Pene J, Desroches A, Paradis L et al (1998) Immunotherapy with Fel d 1 peptides decreases IL-4 release by peripheral blood T cells of patients allergic to cats. J Allergy Clin Immunol 102(4 Pt 1):571–578

    Article  PubMed  CAS  Google Scholar 

  28. Simons FE, Imada M, Li Y et al (1996) Fel d 1 peptides: effect on skin tests and cytokine synthesis in cat-allergic human subjects. Int Immunol 8(12):1937–1945

    Article  PubMed  CAS  Google Scholar 

  29. Worm M, Lee HH, Kleine-Tebbe J et al (2011) Development and preliminary clinical evaluation of a peptide immunotherapy vaccine for cat allergy. J Allergy Clin Immunol 127(1):89–97, 97

    Article  PubMed  CAS  Google Scholar 

  30. Schmitz N, Dietmeier K, Bauer M et al (2009) Displaying Fel d1 on virus-like particles prevents reactogenicity despite greatly enhanced immunogenicity: a novel therapy for cat allergy. J Exp Med 206(9):1941–1955

    Article  PubMed  CAS  Google Scholar 

  31. Gronlund H, Vrtala S, Wiedermann U et al (2002) Carbohydrate-based particles: a new adjuvant for allergen-specific immunotherapy. Immunology 107(4):523–529

    Article  PubMed  CAS  Google Scholar 

  32. Neimert-Andersson T, Thunberg S, Swedin L et al (2008) Carbohydrate-based particles reduce allergic inflammation in a mouse model for cat allergy. Allergy 63(5):518–526

    Article  PubMed  CAS  Google Scholar 

  33. Valenta R, Niespodziana K, Focke-Tejkl M et al (2011) Recombinant allergens: What does the future hold? J Allergy Clin Immunol 127(4):860–864

    Article  PubMed  CAS  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor weist auf folgende Beziehungen hin: U. Raap hat für Beratertätigkeit Honorare der Firma Bencard und Stallergenes erhalten. M. Wagenmann hat für Beratertätigkeit und/oder wissenschaftliche Vorträge und/oder die Teilnahme an klinischen Prüfungen von folgenden Arzneimittelherstellern Zuwendungen erhalten: Allergopharma, Bencard, GlaxoSmithKline (GSK), HAL-Allergie, MSD/Essex-Pharma. O. Pfaar hat für Beratertätigkeit und/oder wissenschaftliche Vorträge und/oder die Teilnahme an klinischen Prüfungen von folgenden Arzneimittelherstellern Zuwendungen erhalten: Allergopharma, ALK-Abelló, HAL-Allergy, Bencard, GlaxoSmithKline (GSK), Eumecom, MSD/Essex-Pharma, Hartington, Stallergenes, Roxall, Lofarma, Artu Biologicals, Febena PHARMA, Optima Pharmaceutische GmbH, CYTOS-Biotechnology, Curalogic, Novartis und LETI.

Author information

Authors and Affiliations

  1. Klinik für Dermatologie, Allergologie und Venerologie, Medizinische Hochschule Hannover, Ricklinger Str. 5, 30449, Hannover, Deutschland

    U. Raap

  2. Hals-Nasen-Ohrenklinik, Universitätsklinikum Düsseldorf, Düsseldorf, Deutschland

    M. Wagenmann

  3. Zentrum für Rhinologie und Allergologie Wiesbaden, HNO-Universitätsklinik Mannheim, Mannheim, Deutschland

    O. Pfaar

Authors
  1. U. Raap
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Wagenmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. O. Pfaar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to U. Raap.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Raap, U., Wagenmann, M. & Pfaar, O. Aktueller Stand der spezifischen Immuntherapie mit Tierepithelien. Hautarzt 62, 657–662 (2011). https://doi.org/10.1007/s00105-011-2159-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00105-011-2159-0

Schlüsselwörter

Keywords

Search

Navigation